Table 1. Characteristics of age-appropriately vaccinated patients 2–59 months of age with invasive pneumococcal disease caused by PCV13 serotypes, Catalonia, Spain, 2012–2016*.
| Pt no. |
Age, mo/sex |
Year |
Age at vaccination |
Schedule |
Clinical manifestation |
Complications |
Outcome |
DT |
Ser |
Vaccine schedule |
| 1 |
19/F |
2012 |
12 mo |
1 |
Complicated pneumonia |
Pleural effusion |
Cured |
PCR |
19A |
UC |
| 2 |
15/M |
2012 |
3 ,5 mo† |
2 + 0 |
Complicated pneumonia |
Empyema, pneumothorax |
Cured |
Culture, PCR |
19A |
UC |
| 3 |
15/F |
2012 |
2, 5, 8 mo |
3 + 0 |
Complicated pneumonia |
Empyema, necrotizing pneumonia, bronchoalveolar fistula, pneumothorax |
Bronchopleural fistula |
PCR |
3 |
UC |
| 4 |
23/M |
2012 |
17 mo |
1 |
Uncomplicated pneumonia |
|
Cured |
Culture |
1 |
UC |
| 5 |
24/M |
2012 |
2, 4, 6, 18 mo |
3 + 1 |
Complicated pneumonia |
Empyema |
Cured |
PCR |
19A |
C |
| 6 |
24/M |
2012 |
12, 21 mo |
2 |
Complicated pneumonia |
Empyema |
Cured |
PCR |
3 |
C |
| 7 |
21/M |
2012 |
3, 5, 7, 15 mo |
3 + 1 |
Complicated pneumonia |
Empyema |
Cured |
PCR |
3 |
C |
| 8 |
38/M |
2012 |
30 mo |
1 |
Bacteraemic
mastoiditis |
Epidural abscess, sigmoid sinus thrombosis |
Hydrocephalus |
PCR |
3 |
C |
| 9 |
9/F |
2013 |
2, 3, 4 mo |
3 + 0 |
Complicated pneumonia |
Necrotizing pneumonia |
Cured |
PCR |
19A |
UC |
| 10 |
12/M |
2013 |
2, 4, 6 mo |
3 + 0 |
Complicated pneumonia |
Empyema, necrotizing pneumonia |
Cured |
PCR |
6B |
UC |
| 11 |
50/F |
2013 |
25 mo |
1 |
Complicated pneumonia |
Empyema |
Cured |
PCR |
3 |
C |
| 12 |
34/M |
2013 |
3, 6, 9, 15 mo |
3 + 1 |
Complicated pneumonia |
Empyema, pneumothorax, bronchopleural fistula |
Cured |
Culture, PCR |
3 |
C |
| 13 |
15/M |
2014 |
2, 4, 7 mo |
3 + 0 |
Osteoarticular
infection |
|
Cured |
Culture |
19A |
UC |
| 14 |
43/M |
2014 |
12, 15 mo |
2 |
Complicated pneumonia |
Empyema, necrotizing pneumonia, bronchopleural fistula |
Cured |
PCR |
3 |
C |
| 15 |
44/F |
2014 |
3, 5, 7, 20 mo |
3 + 1 |
Complicated pneumonia |
Empyema |
Cured |
PCR |
3 |
C |
| 16 |
25/F |
2015 |
2, 4, 6, 14 mo |
3 + 1 |
Complicated pneumonia |
Pleural effusion |
Cured |
Culture |
14 |
C |
| 17 |
29/M |
2015 |
3, 5, 7, 18 mo |
3 + 1 |
Complicated pneumonia |
Necrotizing pneumonia |
Cured |
PCR |
3 |
C |
| 18 |
51/M |
2015 |
2, 4, 6, 16 mo |
3 + 1 |
Complicated pneumonia |
Empyema |
Cured |
PCR |
3 |
C |
| 19 |
49/F |
2015 |
12,14 mo |
2 |
Complicated pneumonia |
Empyema |
Cured |
PCR |
3 |
C |
| 20 |
54/F |
2015 |
3, 5, 7,17 mo |
3 + 1 |
Complicated pneumonia |
Empyema |
Cured |
PCR |
3 |
C |
| 21 |
58/M |
2016 |
14, 16 mo |
2 |
Complicated pneumonia |
Empyema, necrotizing pneumonia |
Pneumatocele |
PCR |
3 |
C |
| 22 |
35/M |
2016 |
2, 5, 9, 18 mo |
3 + 1 |
Complicated pneumonia |
Empyema, necrotizing pneumonia |
Cured |
PCR |
3 |
C |
| 23 |
41/M |
2016 |
3, 4, 7, 16 mo |
3 + 1 |
Complicated pneumonia |
Necrotizing pneumonia |
Cured |
PCR |
3 |
C |
| 24 | 23/M | 2016 | 3, 5, 6, 15 mo | 3 + 1 | Complicated pneumonia | Pleural effusion | Cured | PCR | 3 | C |
*C, completed; DT, diagnostic technique; Pt, patient; Ser, serotype; UC, uncompleted. †Patient resident in Andorra (routine immunization schedule 2+1) and transferred to a participating hospital.